NASDAQ:OXFD - Oxford Immunotec Global Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.85 -0.06 (-0.40 %) (As of 05/22/2019 04:00 PM ET)Previous Close$14.91Today's Range$14.54 - $14.9552-Week Range$11.66 - $19.19Volume301,700 shsAverage Volume136,077 shsMarket Capitalization$395.35 millionP/E Ratio29.12Dividend YieldN/ABeta0.32 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. The company develops and markets T-SPOT.TB test used to test for tuberculosis. It is also developing C6 Borrelia burgdorferi (Lyme) ELISA kit, which measures Lyme specific antibodies; and T-SPOT.CMV test that utilizes its T-SPOT technology platform to measure the strength of a patient's cellular immune response to antigens specific to cytomegalovirus (CMV), as well as provides information for informing management strategies of patients at risk of CMV infection and disease, such as transplant patients. The company markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors internationally. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom. Receive OXFD News and Ratings via Email Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OXFD Previous Symbol CUSIPN/A CIK1586049 Webhttp://www.oxfordimmunotec.com/ Phone44-0-12-3544-2780Debt Debt-to-Equity Ratio0.04 Current Ratio12.60 Quick Ratio12.03Price-To-Earnings Trailing P/E Ratio29.12 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$59.75 million Price / Sales6.62 Cash Flow$0.6510 per share Price / Cash Flow22.81 Book Value$8.12 per share Price / Book1.83Profitability EPS (Most Recent Fiscal Year)$0.51 Net Income$120.78 million Net Margins172.27% Return on Equity13.56% Return on Assets10.71%Miscellaneous Employees215 Outstanding Shares26,623,000Market Cap$395.35 million Next Earnings Date7/30/2019 (Estimated) OptionableNot Optionable Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions What is Oxford Immunotec Global's stock symbol? Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD." How were Oxford Immunotec Global's earnings last quarter? Oxford Immunotec Global PLC (NASDAQ:OXFD) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.14. The business earned $14.79 million during the quarter, compared to analyst estimates of $13.74 million. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The company's quarterly revenue was up 26.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.40) EPS. View Oxford Immunotec Global's Earnings History. When is Oxford Immunotec Global's next earnings date? Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Tuesday, July 30th 2019. View Earnings Estimates for Oxford Immunotec Global. What guidance has Oxford Immunotec Global issued on next quarter's earnings? Oxford Immunotec Global issued an update on its FY 2019 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $69-72 million. What is the consensus analysts' recommendation for Oxford Immunotec Global? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global. Has Oxford Immunotec Global been receiving favorable news coverage? Press coverage about OXFD stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Oxford Immunotec Global earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the stock's share price in the next several days. Who are some of Oxford Immunotec Global's key competitors? Some companies that are related to Oxford Immunotec Global include Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Akers Biosciences (AKER) and Arca Biopharma (ABIO). What other stocks do shareholders of Oxford Immunotec Global own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Immunomedics (IMMU), Intel (INTC), AbbVie (ABBV), Gold Resource (GORO), Sangamo Therapeutics (SGMO), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Halozyme Therapeutics (HALO). Who are Oxford Immunotec Global's key executives? Oxford Immunotec Global's management team includes the folowing people: Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 42)Mr. Stefan C. Linn, Chief Operating Officer (Age 54)Ms. Karen C. Koski, VP of Strategy & Investor Relations Who are Oxford Immunotec Global's major shareholders? Oxford Immunotec Global's stock is owned by many different of retail and institutional investors. Top institutional investors include Redmile Group LLC (7.52%), BlackRock Inc. (4.80%), Man Group plc (1.34%), Morgan Stanley (1.25%), FIL Ltd (1.22%) and Northern Trust Corp (1.12%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global. Which institutional investors are selling Oxford Immunotec Global stock? OXFD stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Penn Capital Management Co. Inc., Penn Capital Management Co. Inc., BlackRock Inc., Parametric Portfolio Associates LLC, Oxford Asset Management LLP, New York State Common Retirement Fund and Essex Investment Management Co. LLC. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global. Which institutional investors are buying Oxford Immunotec Global stock? OXFD stock was purchased by a variety of institutional investors in the last quarter, including FIL Ltd, Morgan Stanley, Man Group plc, Renaissance Technologies LLC, EAM Global Investors LLC, JPMorgan Chase & Co., Marshall Wace LLP and Granite Investment Partners LLC. View Insider Buying and Selling for Oxford Immunotec Global. How do I buy shares of Oxford Immunotec Global? Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Oxford Immunotec Global's stock price today? One share of OXFD stock can currently be purchased for approximately $14.85. How big of a company is Oxford Immunotec Global? Oxford Immunotec Global has a market capitalization of $395.35 million and generates $59.75 million in revenue each year. The company earns $120.78 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe. What is Oxford Immunotec Global's official website? The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/. How can I contact Oxford Immunotec Global? Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected] MarketBeat Community Rating for Oxford Immunotec Global (NASDAQ OXFD)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 212 (Vote Outperform)Underperform Votes: 193 (Vote Underperform)Total Votes: 405MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Hedge Funds - How They Work For Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.